Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
about
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolismThe role of transporters in toxicity and diseaseCharacterization of gastrointestinal absorption of digoxin involving influx and efflux transporter in rats: application of mdr1a knockout (-/-) rats into absorption study of multiple transporter substrateInduction of P-glycoprotein expression and activity by Aconitum alkaloids: Implication for clinical drug-drug interactionsMembrane transporters in drug developmentClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.ABC Transport Proteins in Cardiovascular Disease-A Brief Summary.Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I(1) ]/IC(50) and [I(2) ]/IC(50) criteria in the P-gp decision tree.A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study.The functional influences of common ABCB1 genetic variants on the inhibition of P-glycoprotein by Antrodia cinnamomea extractsA novel application of t-statistics to objectively assess the quality of IC50 fits for P-glycoprotein and other transportersPlasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogsInteraction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of LovastatinEffect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1Predicting drug-drug interactions: an FDA perspectiveLesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).Dietary regulation of P-gp function and expression.Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.Transporter-mediated drug-drug interactions.Drug-permeability and transporter assays in Caco-2 and MDCK cell lines.Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.Inhibition of P-glycoprotein by psychotherapeutic drugs in a canine cell model.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.Minimizing Drug Exposure in the CNS while Maintaining Good Oral Absorption
P2860
Q26799691-87F37E47-100E-49EE-A0E9-1603331E0755Q26999452-165D5C67-6C25-4E81-94AF-2B37B1A44045Q28577650-108A2E65-265B-47FE-B769-BA9E9D705F38Q28833675-0CD21D12-13B4-4BF0-96DC-DD59DDD27205Q29616802-DE3F4534-F7A5-4DD1-8852-B0A600052BC7Q30234940-4C5F6944-351D-4A0C-BB5C-9D7F5BF175CFQ30313271-0922E88F-B4D2-488F-BD8A-C9823CD69A52Q30593585-50A106F7-FDEE-4A04-BFAD-BF21DFADEE6DQ30985909-3A3125DD-A86B-4246-85D5-EE35722552A2Q33433453-107906E1-FB17-4364-BE3D-367810DC2A57Q34290110-2D0642AA-9480-4FD3-86D9-1C094637D29AQ34386899-12BDE265-3D8F-407A-856A-7B4ADEF135B1Q35107752-3E78F4AB-692E-4EA8-A866-C8405511CFBDQ35563235-1E03126B-3B5D-4075-AB2A-D5031279CCE8Q36127201-4A24967D-A7FF-4032-A579-D11084210E45Q36444037-BE5463ED-BA52-4AA3-8D88-8174CFD7A1BFQ36737021-FDA07752-8B8F-424A-9534-A5345036FB8DQ36852518-9E887C42-8E9F-45AE-BE70-23A4010B1689Q36935254-88E5CEFE-5BA5-4A8C-BCCE-A9C1B0E6E5A2Q36973762-57A93DFB-1C74-427D-AFD9-CA533DB2F4C5Q37214533-51E3F9CE-854C-4139-92CD-B13129B7CC4AQ37307966-8C057E07-7F14-40A3-A11D-3833F3F71FB3Q37315965-B7361018-12F8-4FC8-A906-3F56A45E3F8AQ37526981-1E4D76C4-A661-448A-842F-A36E7EE8F957Q37585421-9DC65707-5469-4EBF-92FF-3621243D752EQ37724506-CD349FFB-24D9-4797-9D6D-2455824F5189Q37732337-9B4082D0-7645-4074-A3DD-BE9729E77D07Q37761376-D6C952D0-2920-42D0-88D2-D4649AB183F4Q37905033-32E96A63-01F6-4B6E-8320-C6506BC8CA87Q37958069-49A89278-DA5A-49BE-87D3-F3B2D443883AQ38051447-94158D21-AC39-4218-B1F5-C4C210C81559Q38087695-52DD23E0-4A69-4DF6-B438-671B1346B8B5Q38560740-D4CBFF14-9999-4FE8-9FE6-885D764EDEE8Q38793280-EB816150-45B6-471F-B2F8-5DB2A5351B1BQ38844658-0DBEA924-2DED-4012-B3AA-C2686503FA09Q38860371-35848347-7E25-486F-9A52-8F3E29335567Q39018120-C53C75EF-E055-4E67-89CB-E8E9667B015CQ39031326-E1EEAB7A-51C6-45CE-AD28-DECEC91B71FAQ39145949-82F3EC5C-66E2-4266-95AF-A5F4CF2CC0A1Q39733589-95AE19F6-057E-4D91-BD25-73F2D9286549
P2860
Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Drug-drug interactions mediate ...... using digoxin as a probe drug.
@en
Drug-drug interactions mediate ...... using digoxin as a probe drug.
@nl
type
label
Drug-drug interactions mediate ...... using digoxin as a probe drug.
@en
Drug-drug interactions mediate ...... using digoxin as a probe drug.
@nl
prefLabel
Drug-drug interactions mediate ...... using digoxin as a probe drug.
@en
Drug-drug interactions mediate ...... using digoxin as a probe drug.
@nl
P2093
P2860
P356
P1476
Drug-drug interactions mediate ...... using digoxin as a probe drug.
@en
P2093
K S Fenner
M D Troutman
S Kempshall
P2860
P304
P356
10.1038/CLPT.2008.195
P407
P577
2008-11-05T00:00:00Z